Wojtovich Andrew P, Brookes Paul S
Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):882-9. doi: 10.1016/j.bbabio.2008.03.025. Epub 2008 Apr 8.
Ischemic preconditioning (IPC) affords cardioprotection against ischemia-reperfusion (IR) injury, and while the molecular mechanisms of IPC are debated, the mitochondrial ATP-sensitive K(+) channel (mK(ATP)) has emerged as a candidate effector for several IPC signaling pathways. The molecular identity of this channel is unknown, but significant pharmacologic overlap exists between mK(ATP) and mitochondrial respiratory complex II (succinate dehydrogenase). In this investigation, we utilized isolated cardiac mitochondria, Langendorff perfused hearts, and a variety of biochemical methods, to make the following observations: (i) The competitive complex II inhibitor malonate is formed in mitochondria under conditions resembling IPC. (ii) IPC leads to a reversible inhibition of complex II that has likely been missed in previous investigations due to the use of saturating concentrations of succinate. (iii) Malonate opens mK(ATP) channels even when mitochondria are respiring on complex I-linked substrates, suggesting an effect of this inhibitor on the mK(ATP) channel independent of complex II inhibition. Together, these observations suggest that complex II inhibition by endogenously formed malonate may represent an important activation pathway for mK(ATP) channels during IPC.
缺血预处理(IPC)可对缺血再灌注(IR)损伤起到心脏保护作用。尽管IPC的分子机制仍存在争议,但线粒体ATP敏感性钾通道(mK(ATP))已成为几种IPC信号通路的潜在效应器。该通道的分子特性尚不清楚,但mK(ATP)与线粒体呼吸复合物II(琥珀酸脱氢酶)之间存在显著的药理学重叠。在本研究中,我们利用分离的心脏线粒体、Langendorff灌注心脏以及多种生化方法,得出以下观察结果:(i)在类似于IPC的条件下,线粒体中会形成竞争性复合物II抑制剂丙二酸。(ii)IPC导致复合物II的可逆性抑制,由于之前使用了饱和浓度的琥珀酸,这一现象在以往研究中可能被忽略。(iii)即使线粒体在以复合物I连接的底物进行呼吸时,丙二酸也能打开mK(ATP)通道,这表明该抑制剂对mK(ATP)通道的作用独立于复合物II抑制。这些观察结果共同表明,内源性形成的丙二酸对复合物II的抑制可能是IPC期间mK(ATP)通道的重要激活途径。